Medical/Pharmaceuticals
Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature
SAN FRANCISCO and SUZHOU, China, Dec. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...
2025-12-18 08:00
5175
Nabsys and Hitachi Present Electronic Genome Mapping Data at Japanese Society of Human Genetics (JSHG) 2025 Annual Meeting
TOKYO, Dec. 18, 2025 /PRNewswire/ -- Nabsys 2.0, LLC (Nabsys), a pioneer in electronic genome mapping technology, in partnership with Hitachi High-Tech Corporation (HHT) announces the presentation of high resolution structural variation data on the OhmX(™) platform at the Japanese Society of Huma...
2025-12-18 05:05
3042
PRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction Targets
TOKYO, Dec. 17, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") and Talus Bioscience, Inc. ("Talus Bio") announced today that they entered into a collaboration to discover novel Inhibitors of transcription factor (TF) and protein-protein interaction (PPI) targets. By combining Talus Bio's a...
2025-12-18 00:00
3970
Datasea Advances Deployment of an Acoustics + AI-Driven Next-Generation Beauty & Health Intelligence System, Addressing a Multi-Billion-Dollar China Market Opportunity
BEIJING, Dec. 17, 2025 /PRNewswire/ -- Datasea (Beijing) Technology Co., Ltd. ("Datasea"), a subsidiary of Datasea Inc. (NASDAQ: DTSS), today announced a strategic partnership with Shenzhen Yizhimei Technology Co., Ltd. ("Yizhimei"). Datasea will empower Yizhimei with its Acoustics + AI technolog...
2025-12-17 22:30
4113
Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for Cardiovascular Risk Reduction
SHANGHAI and SANTA BARBARA, Calif., Dec. 17, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, today announced the submission ofRN5681 to the Australian Human Research Ethics Committee (HREC), advancing the company's first bi-valent siRNA into clinical de...
2025-12-17 21:00
5643
MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics
SEOUL, South Korea, Dec. 17, 2025 /PRNewswire/ -- MEDI&GENE, a
biopharmaceutical company developing therapeutics for metabolic diseases,
announced today that it has entered into a Catalyze agreement with
Eli Lilly and Company (Lilly) to advance a next-generation therapeutic for
obesity.
2025-12-17 21:00
3484
Bioptimus Unveils M-Optimus, a World Model for Biology
Revolutionary model represents a transformative step toward AI-powered virtual tissues, patient digital twins, and a new era of data-driven biomedical innovation * The Unveiling of M-Optimus: Bioptimus has trained its inaugural World Model for biology - a foundation model that learns interacti...
2025-12-17 20:00
3053
CUHK and MicroSigX partner to launch a breakthrough test aiding early autism diagnosis offering 200 free test quotas
HONG KONG, Dec. 17, 2025 /PRNewswire/ -- The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) announced the official launch of the world's first "AI-Powered Multikingdom Microbial Biomarkers Technology" (MSX Metagenie®) today, in collaboration with MicroSigX Biotech Diag...
2025-12-17 19:01
4425
Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol
SHANGHAI, Dec. 17, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the U.S. Food and Drug Administ...
2025-12-17 16:10
4436
111, Inc. Announces Third Quarter 2025 Unaudited Financial Results
* Transition from An Asset-Heavy Business Model to An Asset-Light Business Model * Achieved Quarterly Non-GAAP Net Profitability * Maintained Non-GAAP Operational Profitability for Three Consecutive Quarters * Achieved Quarterly Positive Operating Cash Flow SHANGHAI, Dec. 17, 2025 /PRNewswi...
2025-12-17 14:00
2723
Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma
SHANGHAI and HONG KONG, Dec. 17, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2025-12-17 09:00
4143
Aussie medtech Ferronova raises another $6 million to advance image-guided cancer surgery
ADELAIDE, Australia, Dec. 17, 2025 /PRNewswire/ -- Australian company Ferronova has raised a further$6 million to progress the commercialisation of a novel nanoparticle image-guided surgery solution seeking to improve identification of cancer cells and reduce the risk of undetected recurrence fol...
2025-12-17 08:30
3121
Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies
SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, Dec. 16, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced amulti-year, global strategi...
2025-12-17 08:04
3039
Jiaying Pharmaceutical: A New Pathway for the Industrialization of Century-Old Hakka Medicine
HONG KONG, Dec. 17, 2025 /PRNewswire/ -- Recently, Meizhou in Guangdong, known as the "World Capital of the Hakka", welcomed a globally watched event, the Seventh World Hakka Entrepreneurs Convention. At this gathering that drew the attention of Hakka entrepreneurs worldwide, Guangdong Jiaying Ph...
2025-12-17 08:00
2029
KPM Analytics Unveils the SmartChem® 800 Series, a Next-Generation Platform for High-Throughput Wet Chemistry
Industry's highest-capacity discrete analyzer delivers true walk-away automation for commercial laboratories WESTBOROUGH, Mass., Dec. 16, 2025 /PRNewswire/ -- Commercial laboratories face mounting pressure to process more samples with fewer staff while maintaining fast turnaround times. When urg...
2025-12-16 22:00
2485
Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development
* The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters * Proceeds to advance two differentiated and highly competitive ADC programs in global Phase I trials ...
2025-12-16 21:30
2490
Breakthrough Progress: METiS TechBio Publishes Consecutive Research Findings in Nature Communications and the Journal for ImmunoTherapy of Cancer
BEIJING, Dec. 16, 2025 /PRNewswire/ -- METiS TechBio ("METiS") today announced that two of its oncology pipeline candidates,MTS-105 and MTS-107, have been published in leading international peer-reviewed journals,Nature Communications and theJournal for ImmunoTherapy of Cancer (JITC), representin...
2025-12-16 18:59
3302
Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Stock Cod e: 2563.HK), today announced that the first patient has been dosed for one of its key oversea clinical studies: the U.S. pivotal clinical stud...
2025-12-16 12:55
2863
Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development
* The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters * Proceeds to advance two differentiated and highly competitive ADC programs in global Phase I trials ...
2025-12-16 08:30
3129
Enginprime Medical Inc Announces First-in-Human Study of Its Leading OpusOne™ pVAD
HANGZHOU, China, Dec. 15, 2025 /PRNewswire/ -- Enginprime Medical Inc ("Enginprime"), an emerging leader in percutaneous ventricular assist device (pVAD) technologies and a Voyagers Capital portfolio company, today announced that its industry leading pVAD, OpusOne™, has entered its first-in-human...
2025-12-16 06:00
3290
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
49302
The Future of AI 3D Character Workflows: Reallusion CC 5.2 Turns Meshes into Living Characters
2026-10-29 20:03
25021
ROKAE delivers its 10,000th humanoid force-controlled arm
2026-10-27 00:00
21438
